nor-NOHA monoacetate
Based on 7 publication(s) in Google Scholar
nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 2250019-93-1
- Formula: C7H16N4O5
- Molecular Weight:236.23
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Targeted Diversity Library
HY-L099
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) nor-NOHA monoacetate
More- Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
- Free Radic Biol Med. 2026 Apr:247:516-527. [Abstract]
- Chin Med. 2026 May 28;21(1):151. [Abstract]
- Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
- FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
- Clin Immunol. 2024 Sep 3:110355. [Abstract]
- Res Sq. 2026 May 8:rs.3.rs-9404453. [Abstract]
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Bio/Physico-chemical Assay
Biological Activity
nor-NOHA monoacetate (0.1-1 mM, 72 h) induces apoptosis in a dose-dependent manner under hypoxia (1.5% O2) in K562 cells[1].
nor-NOHA monoacetate (1 mM, 72 h) attenuates hypoxia-mediated resistance towards imatinib in K562 or KCL22 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
nor-NOHA monoacetate (100 mg/kg, i.v., once time) increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2250019-93-1
-
Appearance Solid
-
Molecular Weight 236.23
-
Formula C7H16N4O5
-
Color White to off-white
-
SMILES
N[C@H](C(O)=O)CCNC(NO)=N.O=C(C)O
-
Synonyms
Nω-Hydroxy-nor-L-arginine monoacetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Dec 11;188(25):7291-7308.e23. PMID: 41161316
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
Bar plots showing proportions of TNF-α+ T cells in fetal liver whole blood following PMA simulation. T cells were cultured alone (light green) or co-cultured with matched fetal neutrophils (orange) in the presence or absence of ARG1 inhibitor (nonor-NOHA monoacetate; overnight) or L-arginine supplementation, as indicated on the x axis.
-
Free Radic Biol Med
Endothelial Arg2 regulates HIMM-induced mitochondrial hyperfission via affecting arginine metabolism. [Abstract]2026 Apr:247:516-527. PMID: 41720362 -
Chin Med
Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. [Abstract]2026 May 28;21(1):151. PMID: 42210399 -
Front Cell Dev Biol
mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. [Abstract]2021 Dec 23;9:741911. PMID: 35004668
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
nor-NOHA monoacetate (nor-NOHA) efficiently reduced immunosuppressive activity. Arg1 inhibitor (nor-NOHA) and/or iNOS inhibitor [L-NG-Monomethylarginine, Acetate Salt (L-NMMA)] were added in PMN-MDSCs’ suppressive function assays.
-
FASEB J
Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. [Abstract]2025 Sep 30;39(18):e71057. PMID: 40955599
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (1, 10, 50, 100 μM) increased HaCaT cell viability.
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (100 μM) increased K5 expression in HaCaT cells.
-
Clin Immunol
MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia. [Abstract]2024 Sep 3:110355. PMID: 39237078 -
Res Sq
Protective coinfection: influenza reprograms myeloid cells to limit CD8 T cell-mediated malaria pathology. [Abstract]2026 May 8:rs.3.rs-9404453. PMID: 42147182
Solvent & Solubility
DMSO : 100 mg/mL (423.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (211.66 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (423.32 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [Content Brief]
[2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.2332 mL | 21.1658 mL | 42.3316 mL | 105.8291 mL |
| 5 mM | 0.8466 mL | 4.2332 mL | 8.4663 mL | 21.1658 mL | |
| 10 mM | 0.4233 mL | 2.1166 mL | 4.2332 mL | 10.5829 mL | |
| 15 mM | 0.2822 mL | 1.4111 mL | 2.8221 mL | 7.0553 mL | |
| 20 mM | 0.2117 mL | 1.0583 mL | 2.1166 mL | 5.2915 mL | |
| 25 mM | 0.1693 mL | 0.8466 mL | 1.6933 mL | 4.2332 mL | |
| 30 mM | 0.1411 mL | 0.7055 mL | 1.4111 mL | 3.5276 mL | |
| 40 mM | 0.1058 mL | 0.5291 mL | 1.0583 mL | 2.6457 mL | |
| 50 mM | 0.0847 mL | 0.4233 mL | 0.8466 mL | 2.1166 mL | |
| 60 mM | 0.0706 mL | 0.3528 mL | 0.7055 mL | 1.7638 mL | |
| 80 mM | 0.0529 mL | 0.2646 mL | 0.5291 mL | 1.3229 mL | |
| 100 mM | 0.0423 mL | 0.2117 mL | 0.4233 mL | 1.0583 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
nor-NOHA monoacetate Related Classifications
HY-112885B Related Classifications
Powered by Bioz